Skip to content

Clinical trials

Muscular Dystrophies trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscular Dystrophies Country / region: France Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20104
20112
20123
20131
20142
20151
20162
20171
20182
20193
20201
20212
20224
20241
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Terminated6
Unknown status5
Active, not recruiting3
Recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline4
Centre Hospitalier Universitaire de Saint Etienne3
Fulcrum Therapeutics3
Institut de Myologie, France3
Centre Hospitalier Universitaire de Nice2
Centre d'Investigation Clinique et Technologique 8052
PTC Therapeutics2
Assistance Publique - Hôpitaux de Paris1
Association APPROCHE1
Avidity Biosciences, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscular Dystrophies32
Neuromuscular Diseases12
Muscular Dystrophy, Duchenne11
Muscular Diseases9
Musculoskeletal Diseases8
Muscular Dystrophy, Facioscapulohumeral6
Genetic Diseases, Inborn5
Muscular Disorders, Atrophic5
Nervous System Diseases5
Genetic Diseases, X-Linked3

Trials

Showing 76 to 32 of 32. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.